The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to an emailed statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a "vaccine for the world" because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
Russian air strikes kill 10, injure more than 50 in Ukraine's Kyiv
US, Iran talks conclude in Doha, focused on Strait of Hormuz
Trump honours Theodore Roosevelt in North Dakota, debuts new Air Force One
Kenyan court charges 8 schoolgirls with fellow students' murder
At least 5 people killed in fire in Antwerp apartment block
Three people die in Mexico World Cup celebrations as fans crowd streets
After Venezuela quakes, citizens lead rescues amid military theft accusations
Two dead after wildfire guts house in northern Greece
